 Very good evening to Brand Foundation's board members, donors, and our distinguished guests. I am extremely grateful and honoured to be here tonight and to be among the recipients of this year's Brand Foundation research keeps. This is actually the first grant that I applied and I got it this year. So this means a lot to me actually. Thank you very much to the Brand Foundation board members and all the generous donors. First of all, I would like to acknowledge Professor Peter Craig and Dr. Julia Teller, the lab heads of the neuropharmacology lab at the University of Melbourne. There have been so much more than the people that I'm working for now, but also have been great mentors for me in my research career. Also not forgetting the rest of my lab mates in the Craig lab. I would also like to take this opportunity to extend a million thanks to my family and friends for their endless support. Okay. Traumatic brain injury inflicts hundreds of thousands of Australians every year. Traumatic brain injury patients often suffer a lifelong disability that also impacts the life of their loved ones. Research in traumatic brain injury, however, have not yet discovered effective treatment for TBI patients. In our research group, we have identified a key molecular pathways called STING and Type 1 interferon that are responsible in the progressions of neuronal cell death after traumatic brain injury. By blocking these pathways, the injury was reduced as shown in our animal model of traumatic brain injury. So moving forward and with the help of this research ground, we will be screening for a potential compounds to block these pathways and in the hope to find a viable therapeutics for the treatment of traumatic brain injury in the patients. Thank you very much.